INTRODUCTION
============

Upregulation of glial cell line-derived neurotrophic factor (GDNF), a member of the transforming growth factor-β family of trophic factors, can promote neuronal survival, axonal growth, and synapse formation in various neuronal cell populations \[[@ref1], [@ref2]\]. In addition, the dysregulation of GDNF and GDNF family receptor α-1 (GFRα-1) contributes to neuronal death \[[@ref3][@ref4]-[@ref5]\], and GDNF administration has neuroprotective effects against neurotoxin-induced neurodegeneration \[[@ref1], [@ref6], [@ref7]\], suggesting that the GDNF/GFRα-1 signaling pathway is a useful target for the development of anti-neurodegenerative therapies in the adult brain \[[@ref8][@ref9]-[@ref10]\].

Many cellular effects of GDNF are initiated by binding to the specific receptor GFRα-1. One effect is that activation of the GDNF/GFRα-1 signaling pathway stimulates the intracellular Akt/mammalian target of rapamycin (mTOR) signaling pathway \[[@ref11], [@ref12]\]. We recently reported that the transduction of adult dopaminergic neurons with adeno-associated virus serotype 1 (AAV1) with a constitutively active form of ras homolog enriched in brain \[Rheb(S16H)\], which induces the sustained activation of mTOR complex 1 (mTORC1) by a resistance to the tuberous sclerosis 1/2 (TSC1/2), protects the nigrostriatal dopaminergic system through the production of brain-derived neurotrophic factor (BDNF) and GDNF in an animal model of Parkinson's disease \[[@ref10]\]. In the rat hippocampus, we also observed that induction of neuronal BDNF following AAV1-Rheb(S16H) administration contributes to the protection of hippocampal neurons from thrombin-induced neurotoxicity \[[@ref13], [@ref14]\]. However, it is unclear whether Rheb(S16H) transduction of hippocampal neurons can promote the production of GDNF for neuroprotection in the hippocampus *in vivo*. In the present study, we investigate the following questions: whether AAV1-Rheb(S16H) administration upregulates GDNF expression in the hippocampus, whether the upregulation of GDNF is mediated by Rheb(S16H)-induced neuronal neurotrophic factors, and whether the activation of the GDNF/GFRα-1 signaling pathway following AAV1-Rheb(S16H) administration contributes to neuroprotection against thrombin-induced neurotoxicity in the rat hippocampus.

MATERIALS AND METHODS
=====================

Production of AAV viral vectors
-------------------------------

All vectors used in these studies were the AAV1 serotype as previously described \[[@ref10], [@ref14], [@ref15]\]. A plasmid carrying Rheb was purchased from OriGene Technologies (Rockville, MD, USA). Rheb DNA was amplified and modified to incorporate a FLAG-encoding sequence at the 3\'-end by expanded long-template PCR (Roche, Basel, Switzerland). Rheb(S16H) was generated with the Phusion Site-Directed Mutagenesis Kit (New England Biolabs, Ipswich, MA, USA) in the pGEM-T vector (Promega, Madison, WI, USA), and then cloned into an AAV packaging construct that utilizes the chicken β-actin promoter and contains a 3\' WPRE (pBL). AAVs were produced by the University of North Carolina Vector Core, and the genomic titer of Rheb(S16H) was 2×10^12^ viral genomes/ml. Enhanced green fluorescent protein (GFP), used as a control, was subcloned into the same viral backbone, and viral stocks were produced at titers of 1×10^12^ viral genomes/ml.

Institutional review of animal protocols
----------------------------------------

Female Sprague Dawley (SD) rats (10-week-old, 220\~240 g) were obtained from Daehan Biolink (Eumseong, Korea). All animal experiments were conducted in accordance with the Guidelines for Animal Care and Use of Kyungpook National University, approved by the Animal Care Committee at Kyungpook National University (No. KNU 2016-42).

Intra-hippocampal injection
---------------------------

SD Rats were anesthetized with 360 mg/kg chloral hydrate (Sigma, St. Louis, MO, USA) through intraperitoneal injection, and positioned in a stereotaxic apparatus (David Kopf Instrument, Tujunga, CA, USA). Two microliters of the viral vectors were injected into the right hippocampus of the SD rats (AP: −3.8 mm; ML: −2.4 mm; DV: 3.0 mm, relative to the bregma), according to the brain atlas \[[@ref16]\]. Infusions of viral vectors were performed at a rate of 0.1 µl/min over 20 min using 30-gauge injection needles connected to a 10 µl Hamilton syringe. The needle was maintained in position for an additional 5 min to diffuse the materials before being slowly retracted.

To examine the contribution of neurotrophic signal pathways for neuroprotection, we used neutralizing antibodies (NA) \[[@ref10], [@ref14]\]. Three weeks after virus injection, 200 ng of NA alone or in combination with 20 U of thrombin (Sigma) dissolved in 4 µl phosphate-buffered saline (PBS) were injected into the right hippocampal CA1 region as described above \[[@ref13], [@ref14]\]. The following NA were used: anti-BDNF (Santa Cruz Biotechnology, Dallas, TX, USA), anti-GDNF (R&D Systems, Minneapolis, MN, USA), and anti-GFRα-1 (Sigma).

Rapamycin administration
------------------------

To determine the contribution of mTORC1 activity to GDNF induction, SD rats were intraperitoneally injected with the mTORC1 inhibitor, rapamycin (5 mg/kg dissolved in 4% ethanol, 5% Tween 80, and PEG400; LC Laboratory, Woburn, MA, USA) once a day for 3 weeks after AAV1-Rheb(S16H) injection until 4 weeks post-injection \[[@ref10], [@ref14]\].

Immunohistochemical staining
----------------------------

Animals were transcardially perfused, and then fixed brain sections (30 µm thick) were processed for immunohistochemical staining as previously described with some modifications \[[@ref10], [@ref14]\]. Briefly, brain sections were rinsed in PBS and then incubated at 4°C with the primary antibody for 48 hr. After rinsing with PBS containing 0.5% bovine serum albumin, brain sections were incubated at room temperature with the appropriate biotinylated secondary antibody and processed with an avidin-biotin complex kit (Vector Laboratories, Burlingame, CA, USA). The signal was detected by incubating sections in 0.5 mg/ml 3,3\'-diaminobenzidine (Sigma) in 0.1 M PBS containing 0.003% H~2~O~2~. Stained samples were analyzed with bright-field microscopy (Axio Imager, Carl Zeiss, Germany). The primary antibodies were rabbit anti-BDNF (1:200, Santa Cruz Biotechnology), rabbit anti-p-4E-BP1 (1:1,000, Cell Signaling Technology, Danvers, MA, USA), goat anti-GDNF (1:400, R&D Systems), rabbit anti-GFRα-1 (1:100, Sigma), and mouse anti-Neuronal nuclei (NeuN, 1:500; Millipore, Billerica, MA, USA). Brain sections were mounted on gelatin-coated slides, and then analyzed with bright-field microscopy (Axio Imager).

For immunofluorescence labeling, brain sections were rinsed and incubated for 48 hr with one of the following conjugated pairs: mouse anti-NeuN (1:500, Millipore) and rabbit anti-FLAG (1:3,000, Sigma); mouse anti-GFAP (1:2,000, Millipore) and rabbit anti-FLAG (1:3,000, Sigma); mouse anti-GFAP (1:2,000, Millipore) and rabbit anti-p-4E-BP1 (1:1,000, Cell Signaling Technology); mouse anti-NeuN (1:500, Millipore) and goat anti-GDNF (1:200, R&D Systems); mouse anti-GFAP (1:2,000, Millipore) and goat anti-GDNF (1:200, R&D Systems); mouse anti-NeuN (1:500, Millipore) and rabbit anti-GFRα-1 (1:100, Sigma); or mouse anti-GFAP (1:2,000, Millipore) and rabbit anti-GFRα-1 (1:100, Sigma). The sections were then rinsed and incubated with Texas Red-conjugated anti-goat IgG, anti-mouse IgG or anti-rabbit IgG (1:400, Vector Laboratories), and fluorescein isothiocyanate-conjugated anti-rabbit IgG (1:400, Jackson Lab, West Grove, PA, USA) or anti-mouse IgG (1:400, Vector Laboratories) for 1 hr, and then washed and mounted with ProLong Gold antifade reagent (Invitrogen, Carlsbad, CA, USA). Stained sections were viewed using a fluorescence microscope (Axio Imager).

Western blot analysis
---------------------

Western blot analysis was performed as described previously \[[@ref10], [@ref14]\]. Briefly, tissues were homogenized and centrifuged at 4°C for 15 min at 14,000 ×*g*, the supernatant was transferred to a fresh tube, and the concentration was determined using a bicinchoninic acid kit (Bio-Rad Laboratories, Hercules, CA, USA). Samples were boiled at 100°C for 5 min before loading onto the gel, and equal amounts of protein (30 µg) in loading buffer were loaded into each lane. Proteins separated by gel electrophoresis were transferred to polyvinylidene difluoride membranes (Millipore) using an electrophoretic transfer system (Bio-Rad Laboratories). Membranes were incubated overnight at 4°C with the following specific primary antibodies: mouse anti-β-actin (1:1,000, Santa Cruz Biotechnologies), goat anti-GDNF (1:1,000, R&D Systems), rabbit anti-p-4E-BP1 (1:1,000, Cell Signaling Technology), rabbit anti-4E-BP1 (1:1,000, Cell Signaling Technology), rabbit anti-BDNF (1:500, Santa Cruz Biotechnology), and rabbit anti-GFRα-1 (1:1,000, Sigma). After washing, the membranes were incubated with horseradish peroxidase-conjugated anti-rabbit IgG (1:5,000, Santa Cruz Biotechnologies), anti-mouse IgG or anti-goat IgG (1:5,000, Invitrogen) for 1 hr at room temperature. Blots were developed with ECL western blotting detection reagents (GE Healthcare Life Sciences, Little Chalfont, UK). For semi-quantitative analyses, the density of the immunoblot bands was measured with a computer imaging device and accompanying software (Fuji Film, Tokyo, Japan).

Primary astrocyte cultures
--------------------------

Astrocyte cultures were prepared from brains by the method of McCarthy and de Vellis \[[@ref17]\]. Briefly, whole brains were homogenized in a 70-µm strainer. Cells were seeded in T75 culture flasks or 100 mm culture dishes. Cells were cultured at 37°C in a humidified atmosphere containing 5% CO~2~. Culture media were changed initially after 5 days and every 2 days after that, and the cells were used after culture for 14\~21 days. Secondary cultures of pure astrocytes were obtained by shaking mixed glial cultures at 250 rpm for 4 hr, and then the culture medium was discarded. Astrocytes were dissociated using trypsin-EDTA (Life Technologies, Loughborough, UK) and centrifuged at 2,000 rpm for 30 min. Astrocytes obtained were seeded onto plates and cultured in DMEM (Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco, Loughborough, UK) and penicillin-streptomycin (Gibco). Animals used for cell cultures were acquired and cared for in accordance with the guidelines published in the National Institutes of Health *Guide for the Care and Use of Laboratory Animals*.

Quantitative RT-PCR for GFRα-1 expression in astrocytes in vitro
----------------------------------------------------------------

Cultured astrocytes were treated with recombinant human BDNF (100 ng/ml; Peprotech, Seoul, Korea) or GDNF (100 ng/ml; R&D Systems) for 8 hr, and then RNA was extracted from cells with TRIzol reagent (Life Technologies). RNA isolation was performed using the RNeasy Mini Kit (Qiagen, Germantown, MD, USA) according to the manufacturer's instructions. cDNA synthesis was performed at 37°C for 120 min with 100 ng of RNA using a High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Waltham, MA, USA). Quantitative RT-PCR was performed using the one-step SYBR PrimeScript RT-PCR kit (Perfect Real Time; Takara Bio Inc., Shiga, Japan) according to the manufacturer's instructions, followed by detection using an Applied Biosystems 7,500 Real-Time PCR system (Applied Biosystems). GAPDH was used as an internal control. The 2−ΔΔCt method was used to calculate relative changes in gene expression, as determined by real-time PCR experiments.

Primer sequences
----------------

Mouse GFRα-1 Forward: 5'-GGG CAG TCC CGT TCA TAT CA-3'

Reverse: 5'-GGC TGC ATC GAG GCA GTT-3'

Mouse GAPDH Forward: 5'-AAC TTT GGC ATT GTG GAA GG-3'

Reverse: 5'-ACA CAT TGG GGG TAG GAA CA-3'

Counting of hippocampal CA1 neurons and efficiency of AAV1-Rheb(S16H) transduction
----------------------------------------------------------------------------------

CA1 neurons were counted as previously described \[[@ref14]\]. Briefly, alternate sections were obtained at 3.3, 3.6, 4.16, and 4.3 mm posterior to the bregma, and two hippocampal sections from each level (eight regions per animal) were used to count cells in each rectangular area (1×0.05 mm) of CA1 regions. The number of cells was expressed quantitatively as a percentage in comparison with the contralateral control using a light microscope (Axio Imager) at a magnification of 200×.

To measure the efficiency of AAV1-Rheb(S16H) transduction in the hippocampus *in vivo*, FLAG-colocalized neurons and non-neuronal cells such as astrocytes and microglia following double immunofluorescence labeling were counted in four rectangular boxes (1×0.3 mm) in the hippocampus of each animal using a fluorescence microscope (Axio Imager). The ratio of FLAG-colocalized neurons and non-neuronal cells was expressed as a percentage relative to the total number of FLAG-colocalized cells.

Statistical analysis
--------------------

All values are expressed as the mean±standard deviation. Multiple comparisons among groups were performed with the independent samples *t*-test or one-way analysis of variance followed by Tukey's post-hoc tests. All statistical analyses were performed using Sigma Stat software (Systat Software, San Jose, CA, USA).

RESULTS
=======

GDNF upregulation occurs in neurons and astrocytes in the AAV1-Rheb(S16H)-transduced rat hippocampus
----------------------------------------------------------------------------------------------------

In the previous study \[[@ref14]\], we reported that the transduction of Rheb(S16H) using AAV1 was well observed in neurons, but not in glia, and that its neuronal upregulation stimulated the production of neuronal BDNF via mTORC1 activation, contributing to neuroprotection in the hippocampus *in vivo*. Similar to our previous results \[[@ref14]\], following an intra-hippocampal injection of AAV1-Rheb(S16H), the hippocampal tissue shows apparent neuronal expression of the transduced proteins compared to glial expression *in vivo* (98.8% vs. 1.2% for neurons and astrocytes, respectively), as revealed by staining with anti-FLAG antibodies ([Fig. 1B](#F1){ref-type="fig"}), and Rheb(S16H) upregulation induced an increase of BDNF in hippocampal neurons ([Fig. 1C](#F1){ref-type="fig"}) at 3 weeks after viral injection ([Fig. 1A](#F1){ref-type="fig"}). In addition, we observed that Rheb(S16H) transduction significantly increased protein levels of BDNF compared to those in the contralateral hippocampus, as demonstrated by western blotting at 3 weeks after an intra-hippocampal injection ([Fig. 1A and 1D](#F1){ref-type="fig"}; \*p\<0.05 *vs*. contralateral controls). Although Rheb(S16H) expression was mainly observed in neurons in the Rheb(S16H)-transduced hippocampus ([Fig. 1B](#F1){ref-type="fig"}), the results of immunohistochemical staining at 3 weeks after viral injection ([Fig. 1A](#F1){ref-type="fig"}) showed that the activation of mTORC1, as indicated by increases in phosphorylated 4E-BP1 (p-4E-BP1; [Fig. 2A](#F2){ref-type="fig"}), and GDNF upregulation ([Fig. 2B](#F2){ref-type="fig"}) were observed in both neurons and astrocytes in the AAV1-Rheb(S16H)-injected rat hippocampus. Western blotting also showed that the levels of p-4E-BP1 and GDNF were significantly increased in the Rheb(S16H)-transduced hippocampus compared to the contralateral hippocampus ([Fig. 2C](#F2){ref-type="fig"}; \*p\<0.05 vs. contralateral controls). There was no change in p-4E-BP1 and GDNF levels in the hippocampus treated with AAV1-GFP ([Fig. 2C](#F2){ref-type="fig"}).

To examine whether the upregulation of GDNF is mediated by mTORC1 activation following Rheb(S16H) transduction, we measured the protein levels of p-4E-BP1 and GDNF after intraperitoneal injections of rapamycin, a specific inhibitor for mTORC1 \[[@ref10], [@ref14]\], for 7 days ([Fig. 1A](#F1){ref-type="fig"}). As demonstrated by western blotting, treatment with rapamycin significantly reduced the protein levels of p-4E-BP1 compared to those in intact controls and Rheb(S16H)-transduced rats that received no rapamycin \[[Fig. 2D](#F2){ref-type="fig"}; \*p\<0.05 *vs*. intact controls and Rheb(S16H) alone\]. In addition, we observed that the upregulation of GDNF in the Rheb(S16H)-treated hippocampus ([Fig. 2C](#F2){ref-type="fig"}) was significantly attenuated by rapamycin treatment ([Fig. 2D](#F2){ref-type="fig"}), indicating that the induction of GDNF was mediated by mTORC1 activation in the Rheb(S16H)-transduced hippocampus.

Upregulation of GFRα-1 expression in the Rheb(S16H)-transduced hippocampus
--------------------------------------------------------------------------

GFRα-1, a receptor specific for GDNF, is necessary for many cellular effects of GDNF in the brain, and the activation of the GDNF/GFRα-1 signaling pathway is important for neuronal survival and proper function in various neuronal cell populations \[[@ref1], [@ref2], [@ref12]\]. In the Rheb(S16H)-transduced hippocampus, we additionally observed that the protein levels of GFRα-1 were increased both in hippocampal neurons and astrocytes, as demonstrated by immunohistochemical staining and western blotting at 3 weeks after viral injection ([Fig. 3A, 3B, and 3C](#F3){ref-type="fig"}; \*p\<0.01 *vs*. controls). Moreover, the increases in GFRα-1 expression by Rheb(S16H) transduction were significantly inhibited by treatment with NA against BDNF or GDNF, respectively, as demonstrated by western blotting at 1 day after NA treatment \[[Fig. 1A](#F1){ref-type="fig"} and [4A](#F4){ref-type="fig"}; \*p\<0.05 *vs*. Rheb(S16H) alone\], suggesting that the upregulation of GFRα-1 is mediated by increases in neurotrophic factors such as BDNF or GDNF following Rheb(S16H) transduction.

Other reports have shown that GDNF and BDNF each could play a role as a potent inducer for GFRα-1 expression in neurons \[[@ref18], [@ref19]\]. However, it is unclear whether the upregulation of GDNF and BDNF can induce an increase in GFRα-1 expression in astrocytes. To determine whether these factors induced by Rheb(S16H) transduction contribute to the upregulation of GFRα-1 in astrocytes *in vivo* ([Fig. 3](#F3){ref-type="fig"}), we investigated GFRα-1 expression in the Rheb(S16H)-transduced hippocampus with or without NA against BDNF or GDNF, and measured gene levels of GFRα-1 in primary astrocyte cultures treated with 100 ng/ml recombinant BDNF or GDNF. Astrocytic GFRα-1 upregulation was attenuated by treatment with GDNF NA, but not BDNF NA, in the Rheb(S16H)-transduced hippocampus ([Fig. 4B](#F4){ref-type="fig"}). Consistently, the results obtained by quantitative RT-PCR for GFRα-1 showed that GDNF treatment significantly increased the levels of GFRα-1 mRNA in astrocytes compared to that in cells receiving vehicle only ([Fig. 4C](#F4){ref-type="fig"}; \*p\<0.001 *vs*. controls), but not in BDNF-treated astrocytes ([Fig. 4D](#F4){ref-type="fig"}). However, treatment with NA against BDNF significantly attenuated the upregulation of astrocytic GDNF levels seen in the Rheb(S16H)-transduced hippocampus compared to the levels in Rheb(S16H) alone \[[Fig. 4A](#F4){ref-type="fig"}; \*p\<0.05 *vs*. Rheb(S16H) alone\]. These results suggest that the increase in astrocytic GFRα-1 following Rheb(S16H) transduction in the hippocampus *in vivo* is mediated by GDNF upregulation, and that BDNF may indirectly contribute to the induction of GFRα-1, even though there was no increase in the expression of GFRα-1 in the BDNF-treated astrocyte cultures.

Neuroprotection by the activation of the GDNF/GFRα-1 signaling pathway in the Rheb(S16H)-transduced hippocampus *in vivo*
-------------------------------------------------------------------------------------------------------------------------

To examine neuroprotective effects of upregulated GDNF and GFRα-1 expression in the hippocampus ([Fig. 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}), we evaluated the effects of treatment with NA against GDNF and GFRα-1, respectively, in the Rheb(S16H)-transduced hippocampus. Rats received a unilateral injection of thrombin, which can act as a neurotoxin in the hippocampus \[[@ref13], [@ref14]\], at 3 weeks after viral injection, and then the hippocampal sections were immunohistochemically stained with anti-NeuN at 1 week after thrombin treatment or co-treatment with thrombin and NA ([Fig. 1A](#F1){ref-type="fig"}). Immunohistochemical staining showed that Rheb(S16H) transduction of hippocampal neurons significantly preserved the number of NeuN-positive neurons from thrombin-induced neurotoxicity in the hippocampal CA1 regions by 92% compared to that of the contralateral controls ([Fig. 5](#F5){ref-type="fig"}; \#p\<0.001 *vs*. thrombin alone). However, the inhibition of GDNF, GFRα-1, and BDNF signaling with those specific NA significantly attenuated the neuroprotective effects of Rheb(S16H) transduction by 23%, 31% and 24%, respectively, compared to Rheb(S6H) and thrombin treated group \[[Fig. 5](#F5){ref-type="fig"}; ^\$^p\<0.05 *vs*. Rheb(S16H) and thrombin\]. These results show that the activation of GDNF/GFRα-1 signaling following Rheb(S16H) transduction contributes to the protection of hippocampal neurons from thrombin-induced neurotoxicity in the hippocampus *in vivo*.

DISCUSSION
==========

GDNF is an important neurotrophic factor that protects neurons in the brain, and the activation of the GDNF/GFRα-1 signaling pathway modulates neuronal survival in various adult neurons \[[@ref1], [@ref10], [@ref12], [@ref20], [@ref21]\]. Other reports show that the expression levels of GDNF and GFRα-1 are dysregulated in patients with neurodegenerative diseases such as Alzheimer's disease \[[@ref3][@ref4]-[@ref5]\], and that the upregulation of GDNF by drug treatments or gene delivery could induce hippocampal neuroprotection \[[@ref22], [@ref23]\]. Thus, the consistent upregulation of the GDNF-mediated signaling pathway can be considered an effective strategy against neurotoxicity and neurodegeneration in the adult brain.

GFRα-1 is a receptor specific for GDNF, and many of the cellular effects of its binding to GFRα-1 are mediated by a cascade of intracellular signaling pathways, most notably that of Ret tyrosine kinase, which results in the downstream activation of the Akt pro-survival pathway that includes mTORC1 activation \[[@ref10], [@ref12], [@ref24], [@ref25]\]. Recently, Konishi et al. \[[@ref4]\] reported that neurons lacking GFRα-1 did not respond to GDNF with neuronal survival, whereas production of GFRα-1 in neurons with dysregulated GFRα-1 restored the GDNF-mediated signaling pathway for neuronal survival, suggesting that the upregulation of GFRα-1 is also important for the induction of neuroprotective effects in the adult brain.

mTORC1, which can be stimulated by various neurotrophic factors, is a serine/threonine kinase that acts as a neuronal survival factor in the adult brain \[[@ref15], [@ref26]\]. We previously reported that the sustained activation of mTORC1 by neuronal transduction with Rheb(S16H) could induce the production of neurotrophic factors such as BDNF and GDNF in dopaminergic neurons in the substantia nigra of adult brain *in vivo* \[[@ref10]\], and that the increases in neurotrophic factors following Rheb(S16H) transduction contributed to neuroprotection in an animal model of Parkinson's disease \[[@ref10]\].

Similar to the upregulation of BDNF in dopaminergic neurons in the substantia nigra \[[@ref10]\], we recently reported that Rheb(S16H) transduction of hippocampal neurons could induce the production of neuronal BDNF through the activation of an mTORC1-mediated signaling pathway *in vivo*, resulting in protection of hippocampal neurons from thrombin-induced neurotoxicity \[[@ref14]\]. In the present study, we additionally found that increases in GDNF expression following Rheb(S16H) transduction were observed both in neurons and astrocytes in the hippocampus of rat brain ([Fig. 2B](#F2){ref-type="fig"}), even though the transduction of Rheb(S16H) using AAV1 was mainly observed in neurons ([Fig. 1B](#F1){ref-type="fig"}) \[[@ref14]\]. These findings suggest that activation of the neurotrophic signaling pathway may occur through interactions between neurons and astrocytes in the Rheb(S16H)-transduced hippocampus.

In addition, GFRα-1 upregulation was also observed both in neurons and astrocytes in the Rheb(S16H)-transduced hippocampus ([Fig. 3A and 3B](#F3){ref-type="fig"}), and GDNF treatment, which could stimulate the induction of GFRα-1 in neurons \[[@ref19]\], increased GFRα-1 expression in astrocyte cultures ([Fig. 4C](#F4){ref-type="fig"}). Consistent with our results, previous studies showed that GDNF could exert a trophic effect on astrocytes through GFRα-1 activation \[[@ref27]\], and that GFRα-1 might be a mediator of autoregulation of GDNF \[[@ref28], [@ref29]\]. BDNF could also act as a potent inducer for GFRα-1 expression in neurons \[[@ref18]\]. However, our results show that neutralization of BDNF did not alter astrocytic GFRα-1 upregulation in the Rheb(S16H)-expressed hippocampus ([Fig. 4B](#F4){ref-type="fig"}), even though its neutralization decreased the expression of neuronal GFRα-1 ([Fig. 4B](#F4){ref-type="fig"}). Moreover, treatment with BDNF did not increase GFRα-1 expression in astrocyte cultures ([Fig. 4D](#F4){ref-type="fig"}), suggesting that the upregulation of neuronal GDNF following Rheb(S16H) transduction might stimulate astrocytic GFRα-1 activation and upregulation in the hippocampus *in vivo*.

Although the induction of BDNF following Rheb(S16H) transduction may be not associated with astrocytic GFRα-1 upregulation, there are many reports showing that BDNF has the potential to induce trophic effects in astrocytes \[[@ref30][@ref31][@ref32]-[@ref33]\]. Furthermore, we recently reported that the increase in neuronal BDNF following Rheb(S16H) transduction could stimulate astroglial activation to produce ciliary neurotrophic factor, also contributing to neuroprotection as well as BDNF \[[@ref34]\]. As demonstrated in [Fig. 4A and 4B](#F4){ref-type="fig"}, the inhibition of GDNF and BDNF activity in the Rheb(S16H)-treated hippocampus attenuated the upregulation of GDNF in both neurons and astrocytes. Collectively, our results suggest that the upregulation of astrocytic GFRα-1 following Rheb(S16H) transduction of hippocampal neurons may be mediated by the increase in GDNF expression, but not by BDNF, and that astrocytic GDNF upregulation through the activation of neurotrophic signaling pathways between neurons and astrocytes can contribute to protection of hippocampal neurons against neurotoxicity ([Fig. 5](#F5){ref-type="fig"}).

In summary, we have identified additional mediators, GDNF and GFRα-1, that are associated with Rheb(S16H)-induced neuroprotection in the hippocampus *in vivo*. In addition to the production of neuronal BDNF following Rheb(S16H) transduction \[[@ref14]\], the present study demonstrates that Rheb(S16H) transduction of hippocampal neurons stimulates the induction of GDNF and GFRα-1 in neurons and astrocytes. Furthermore, our results show that the activation of the GDNF/GFRα-1 signaling pathway, an effect that can be indirectly stimulated by neuronal BDNF, occurs through the upregulation of those factors, and contributes to neuroprotection against thrombin-induced neurotoxicity in the hippocampus ([Fig. 6](#F6){ref-type="fig"}).
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![Experimental schematic and transduction of hippocampal neurons with AAV1-Rheb(S16H) in SD rats. (A) Experimental schematic for investigating the effects of AAV1-Rheb(S16H) administration in the rat hippocampus *in vivo*. (B) Double immunofluorescence staining to visualize co-expression patterns of FLAG and NeuN, or FLAG and GFAP in the Rheb(S16H)-transduced hippocampus. Scale bar, 50μm. The graph represents the ratio of FLAG-colocalized cells between neurons and non-neuronal cells in the AAV1-Rheb(S16H)-injectied hippocampus (n=3 per group). (C) Immunohistochemical staining of BDNF expression following to Rheb(S16H) transduction of hippocampal neurons *in vivo*. Lower images are magnified photomicrographs of the insets. Scale bars: upper images, 100 μm; lower images (insets), 20 μm. (D) Western blot analysis for BDNF expression in the controls, AAV1-GFP- and AAV1-Rheb(S16H)-injected hippocampus of rat brains. Differences among groups were evaluated by one-way analysis of variance and Tukey's post-hoc test (\*p\<0.05 *vs*. CON; n=3 per group).](EN-29-164-f1){#F1}

![mTORC1 activation and GDNF upregulation in the Rheb(S16H)-transduced hippocampus. (A) Immunohistochemical staining results of p-4E-BP1, indicating mTORC1 activation, showed increases in p-4E-BP1 expression in neurons (arrow heads) and non-neuronal cells (arrows), as demonstrated in the magnified photomicrographs of the rectangular insets in the CA1 layer in the Rheb(S16H)-transduced hippocampus. Scale bars: upper images, 100 μm; center images (insets), 20 μm. Astrocytic mTORC1 activation in the Rheb(S16H)-expressed hippocampus was confirmed by double immunofluorescence staining for GFAP and p-4E-BP1 (green arrows). Scale bar: lower images, 20 μm. (B) Double immunofluorescence staining to visualize co-expression patterns of GDNF and NeuN, or GDNF and GFAP in the Rheb(S16H)-transduced hippocampus. Scale bar, 50 μm. (C) Western blot analysis for p-4E-BP1, 4E-BP1, and GDNF expression in the controls, AAV1-GFP- and AAV1-Rheb(S16H)-injected hippocampus of rat brains. Differences among groups were evaluated by one-way analysis of variance and Tukey's post-hoc test (\*p\<0.05 *vs*. CON; n=3 per group). (D) Western blot analysis for mTORC1 activity (p-4E-BP1 and 4E-BP1) and GDNF expression in the hippocampus of rats treated with rapamycin (5 mg/kg) and AAV1-Rheb(S16H) compared to AAV1-Rheb(S16H) alone. Differences among groups were evaluated by one-way analysis of variance and Tukey's post-hoc analysis \[\*p\<0.05 vs. CON, \#p\<0.01 *vs*. Rheb(S16H) alone; n=3 per group\].](EN-29-164-f2){#F2}

![Increases in GFRα-1 expression in the AAV1-Rheb(S16H)-treated hippocampus. (A) Representative images of immunostaining for GFRα-1. Immunohistochemical staining results showed the increases in GFRα-1 expression both in neurons (arrow heads) and non-neuronal cells (arrows) in the Rheb(S16H)-expressing hippocampus, as demonstrated by the magnified photomicrographs of the insets in the CA1 layer. Scale bars: upper images, 100 μm; lower images (insets), 20 μm. (B) Double immunofluorescence staining to visualize co-expression patterns of GFRα-1 and NeuN, or GFRα-1 and GFAP in the Rheb(S16H)-transduced hippocampus. Scale bars: images in first three columns from left, 50 μm; images in far-right column (insets), 20 μm. (C) Western blot analysis for GFRα-1 expression in the controls, AAV1-GFP- and AAV1-Rheb(S16H)-injected hippocampus of rat brains. Differences among groups were evaluated by one-way analysis of variance and Tukey's post-hoc analysis; (\*p\<0.01 *vs*. CON; n=3 per group).](EN-29-164-f3){#F3}

![Astrocytic GDNF and GFRα-1 expression following increases in neurotrophic factors *in vivo* and *in vitro*. (A, B) Western blot (A) and immunohistochemical (B) analysis for GDNF and GFRα-1 expression in the hippocampus of AAV1-Rheb(S16H)-injected rat brains, with or without neutralizing antibodies (NA; 200 ng) against BDNF or GDNF. Differences among groups were evaluated by one-way analysis of variance and Tukey's post-hoc analysis \[\*p\<0.05 *vs*. Rheb(S16H) alone; n=3 per group\]. Scale bar, 100 μm. (C, D) Quantitative RT-PCR analyses for GFRα-1 in primary astrocyte cultures showed significant increases in GFRα-1 expression in the GDNF (100 ng/ml; C)-treated astrocyte cultures compared to vehicle-treated controls (CON), but no change in response to treatment with BDNF (100 ng/ml; D). Differences among groups were evaluated by t-test analysis (\*p\<0.001 *vs*. CON; n=3 per group).](EN-29-164-f4){#F4}

![Activation of the GDNF/GFRα-1 signaling pathway contributes to Rheb(S16H)-induced neuroprotection in the hippocampus. Rats received an AAV injection, and then immunohistochemical staining for NeuN was performed to count the number of preserved neurons in the CA1 regions of the hippocampus at 7 days after treatment with thrombin (Thr.; 20 U) and neutralizing antibodies (NA; 200 ng) against GDNF, GFRα-1, or BDNF, or thrombin alone ([Fig. 1A](#F1){ref-type="fig"}). Right panels are magnified photomicrographs of the rectangular insets in the CA1 layer. Scale bars: left column, 500 μm; right column (insets), 100 μm. The number of NeuN-positive hippocampal neurons in each CA1 layer was quantitatively expressed as a percentage compared to that of the contralateral control. Differences among groups were evaluated by one-way analysis of variance and Tukey's post-hoc analysis; \[\*p\<0.001, ^\#^p\<0.001, and ^\$^p\<0.05 *vs*. CON, thrombin alone, Rheb(S16H)+thrombin, respectively; n=3 per group\].](EN-29-164-f5){#F5}

![Representative schematic of neurotrophic signaling pathway in the Rheb(S16H)-transduced hippocampus. Rheb(S16H) transduction of hippocampal neurons causes the induction of neurotrophic factors such as BDNF and GDNF. Increases in those factors stimulates astroglial activation, resulting in additional GDNF production. The induction of neurotrophic factors in both neurons and astrocytes contributes to neuroprotection in the adult hippocampus.](EN-29-164-f6){#F6}

[^1]: These authors contributed equally to this work.
